Participated · Seed · Feb 2025

Reverb Therapeutics uses its Amplify•R™ platform, which combines bispecific antibody engineering with data-driven modeling, to modulate endogenous cytokines and redirect them to specific tissues. The platform is designed to avoid systemic toxicity, immunogenicity, and manufacturing issues that have limited prior cytokine therapies. Reverb’s initial focus areas are cancer and autoimmune diseases, and in vivo preclinical studies have shown proof-of-concept for tumor shrinkage and cytokine redirection. Its lead program, AMP01, blocks PD-1 while delivering endogenous IL-15 to expand and activate cytotoxic T cells. With the recently closed financing, the company plans to advance the IL-15 bispecific to candidate stage and to develop additional bispecific programs across other cytokines and cellular targets. Elements of the Amplify•R™ antibodies are reusable, enabling rapid scaling of the pipeline across multiple disease areas.

Participated · Series A · Dec 2024

TRIO Pharmaceuticals is a biotechnology company pioneering bispecific antibodies through its proprietary TRAILBody and TIE‑ADC platforms. Its dual‑action therapies aim to directly stop tumor growth while selectively reversing tumor immunosuppression without targeting existing immune checkpoints. TRIO is advancing programs against high‑mortality cancers including multiple myeloma, acute myeloid leukemia, ovarian, endometrial, and triple‑negative breast cancer. The company positions its therapies as potent, less toxic alternatives to conventional treatments and notes its team has developed first‑in‑class FDA‑approved drugs. TRIO will use proceeds to expand preclinical activities and advance its programs toward clinical development. The financing underscores a focus on accelerating development for cancers with high unmet need. TRIO Pharmaceuticals was founded by Purdue University biophysics and structural biology alumnus Shiva Bhowmik, who serves as founder and chief operating officer. The company develops antibody-based therapeutics intended to strengthen the body’s immune response by selectively eliminating immunosuppressive cells and directly targeting cancer cells. TRIO’s approach combines removal of immunosuppressive cells with direct anticancer activity to achieve stronger antitumor immunity. The recent financing is intended to enable TRIO to advance its technology and identify the best drug candidates for further development. Company leadership expects the milestone will open opportunities for collaborations with large pharmaceutical companies and the possibility of raising future funding rounds.